Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONNECT
NCT05965700Phase 2Completed
- Sponsor
- NervGen Pharma Corp.
- Start
- Aug 2023
- Primary completion
- Dec 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in spinal cord injury (SCI) comparing NVG-291 for SC Injection with Placebo for SC Injection (2 arms). Primary endpoint: Objective electrophysiological measures of descending connectivity at 12 weeks. Started Aug 2023; status: completed.
02
Drugs
NVG-291
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT05965700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05965700.